What is the current stock price of Altimmune, Inc. (ALT)?

As of the latest market data, Altimmune, Inc. (ALT) is trading at $2.98. The stock has seen a gain of 1.71% today.

Does Altimmune, Inc. (ALT) pay a dividend?

Based on current data, Altimmune, Inc. does not have a confirmed active dividend policy.

What is the market cap of Altimmune, Inc.?

The current market capitalization of Altimmune, Inc. (ALT) is approximately unavailable.

ALT

Altimmune, Inc.·Healthcare

2.98

1.706%(+0.05)

Close Price

3.08

3.356%(+0.10)

After Hours

Last Updated: — ET

52W L: $2.5652W H: $7.73

ALT NEWS

globenewswire.com

16h ago

Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:

globenewswire.com

17h ago

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide at 24 weeks GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2b trial demonstrated that treatment with pemvidutide, an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist, is associated with concurrent improvements across multiple non-invasive tests (NITs) of metabolic dysfunction-associated steatohepatitis (MASH) activity and fibrosis.

gurufocus.com

5d ago

FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for HepcludexÂ (bulevir

zacks.com

5d ago

Here's Why You Should Add Altimmune Stock to Your Portfolio Now

ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data fueling investor focus.

zacks.com

May 14

Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil

ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.

seekingalpha.com

May 14

Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2017-05-26

Beta

0.17

Websitealtimmune.com↗